Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A.
10.3760/cma.j.issn.1003-9406.2020.05.021
- Author:
Wanqian CAO
1
;
Ruxu ZHANG
Author Information
1. Department of Neurology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China. zhangruxu@vip.163.com.
- Publication Type:Journal Article
- MeSH:
Cell Differentiation;
Charcot-Marie-Tooth Disease;
genetics;
pathology;
therapy;
Genetic Testing;
Humans;
Schwann Cells;
cytology
- From:
Chinese Journal of Medical Genetics
2020;37(5):578-583
- CountryChina
- Language:Chinese
-
Abstract:
Charcot-Marie-Tooth disease (CMT) is the commonest form of inherited neuropathy and has an incidence of 1/2500. CMT1A is the commonest subtype of CMT, which is caused by duplication of peripheral myelin protein 22 (PMP22) gene and accounts for approximately 50% of CMT diagnosed by genetic testing. Duplication of PMP22 may influence the production of PMP22 mRNA and protein, and interfere with the proliferation, differentiation and apoptosis of Schwann cells. In addition, deregulation of NRG1/ErbB pathway and lipid metabolism can also lead to dysfunction of Schwann cells. Such factors may disturb the myelination process, leading to axon degeneration, muscle weakness, and atrophy subsequently. Accordingly, drug therapies for CMT1A are developed by targeting such factors. PXT3003, antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are supposed to down-regulate the level of PMP22 mRNA, while recombinant human NRG-1 (rhNRG1) and neurotrophin-3 (NT-3) may enhance Schwann cells survival and differentiation. In addition, lipid-supplemented diet may remedy the defect of lipid metabolism and maintain the proper structure of myelin. Other targeting drugs include ascorbic acid, progesterone antagonists, IFB-088, ADX71441, and ACE-083. This review is to sum up the pathogenesis of CMT1A and promising targeting drug therapies for further research.
